T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy
GGGuido GhilardiJAJoseph A. FraiettaJNJames N. GersonVMVivianna M. Van DeerlinJJJennifer J.D. Morrissette
Hospital of the University of Pennsylvania · UPMC Hillman Cancer Center · +2 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
251
total citations
- FWCI
- 62.92
- Percentile
- 100%
- References
- 50
Citations per year
Authors
33- GGGuido Ghilardi
Hospital of the University of Pennsylvania, UPMC Hillman Cancer Center, University of Pennsylvania
- JAJoseph A. Fraietta
University of Pennsylvania
- JNJames N. Gerson
Hospital of the University of Pennsylvania, UPMC Hillman Cancer Center, University of Pennsylvania
- VMVivianna M. Van Deerlin
Hospital of the University of Pennsylvania
- JJJennifer J.D. Morrissette
Hospital of the University of Pennsylvania
Topics & keywords
Topics
Keywords
- Medicine
- Lymphoma
- Chimeric antigen receptor
- Malignancy
- CD8
- Lymph node
- Lung cancer
- Immunotherapy
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.